HPV Is the Culprit in Virtually All Cervical Cancers--NIH Panel

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

BETHESDA, Md--Of the 4,900 US deaths each year from cervical cancer, virtually all could have been prevented by routine Pap smears, and nearly all cases could be prevented by practicing safe sex to avoid infection with the human papillomavirus (HPV), a panel of independent experts appointed by the NIH said in a consensus statement.

BETHESDA, Md--Of the 4,900 US deaths each year from cervical cancer,virtually all could have been prevented by routine Pap smears,and nearly all cases could be prevented by practicing safe sexto avoid infection with the human papillomavirus (HPV), a panelof independent experts appointed by the NIH said in a consensusstatement.

The statement was developed at the 3-day Consensus DevelopmentConference on Cervical Cancer, sponsored by the National CancerInstitute and the NIH's Office of Medical Applications of Research.

The panel found that about half of the 15,700 US women diagnosedwith cervical cancer each year have never had a Pap test. Thoseleast likely to be screened include older women, the uninsured,ethnic minorities, and the poor, especially in rural areas.

The panel called cervical cancer "the first major solid tumorto have been shown to be virally induced in essentially everycase. HPV DNA is found in virtually all cervical carcinomas andprecursor lesions worldwide."

Detecting the Preinvasive Stage

The report went on to say that "the majority of these cancersgo through a preinvasive stage that can be detected in the earlystage by a Pap smear and treated with nearly uniform success andthe retention of fertility."

Because HPV is sexually transmitted, the panel said that adolescentsshould be encouraged to delay onset of sexual intercourse andto use barrier methods of contraceptives if they are sexuallyactive. The committee also advised the development of effectiveprophylactic and therapeutic vaccines against HPV.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content